Organization: Bioniche Life Sciences Inc

Bioniche spins out human health subsidiary

Bioniche Life Sciences Inc, Belleville ON, is creating a wholly own subsidiary from its core human health technology to attract external investment and boost the value of the corporation. Bioniche Therapeutics Corp will function as a standalone unit with its own CEO and will seek external revenues through private equity or licensing income derived from…

Bioniche seeking new financial resources

Bioniche Life Sciences Inc is seeking additional financial resources to accommodate “intensive resource allocations” devoted to several late-stage development projects, according to the Belleville ON-based firm’s financial statements for Q2/13. The biopharmaceutical firm reported a 19% increase in quarterly sales from its animal health products to $8.8 million or $15.4 million on a year-to-date basis.…

U15 hires staff and sets up shop in Ottawa

The U15 Group of Canadian Research Universities — a new organization established to represent Canada’s top 15 research-intensive universities — has established an office at the Univ of Ottawa and hired Suzanne Corbeil as its inaugural executive director (see page 7). U15 was formed last year to better represent the priorities and concerns of the…

Bioniche opens animal vaccine production facility

Bioniche Life Sciences Inc has opened Canada’s largest livestock vaccine manufacturing facility using $25 million in repayable loans from the federal and Ontario government’s The Animal Health and Food Safety Vaccine Manufacturing Centre, located at the firm’s headquarters in Belleville ON, is a scale-up facility and the first milestone in a planned $100-million project (R$,…

Bioniche signs agreement for veterinary technology

Bioniche Life Sciences Inc, Belleville ON, has signed an agreement with Trophogen Inc, Rockville MD, to gain commercial access to its proprietary superagonist hormone technology platform. The technology will be developed into a next generation follicle stimulating hormone that will greatly increase receptor binding activity as well as vitro and in vivo potency. The two…

Bioniche follows good FY, with promising new deal

Bellville ON-based Bioniche Life Sciences Inc has released its FY09 year-end results that show significant improvement in revenue generation as sales from its animal health products continue to rise. Sales for FY09 were up 21% to $33.3 million while gross R&D expenses declined 16.7% to $13.3 million. The majority of R&D was devoted to Phase…

AAFC loans $5M to Bioniche vaccine scale-up facility

Bioniche Life Sciences Inc has received another funding commitment as part of its planned $100-million project to create an Animal Health and Food Safety Vaccine Manufacturing Centre at its headquarters in Belleville ON. The latest financial assistance is a $5-million repayable loan from the new Agri-Opportunities Program at Agriculture and Agri-Food Canada. The funding will…

Bioniche Life Sciences puts Irish unit up for sale

Bioniche Life Sciences Inc, Belleville ON, is placing its majority stake in Bioniche Pharma Group Ltd, Galway Ireland, to generate revenue to support the parent’s R&D projects. The announcement was made as the firm announced its financial results for fiscal 2005, ending June 30. If a buyer is secured, Bioniche will use the proceeds to…

Bioniche projects receive $17.6 million from TPC

Bioniche Life Sciences Inc has received $17.2 million from Technology Partnerships Canada (TPC) for two R&D projects that will create nearly 600 jobs in Belleville ON. TPC is providing $7.6 million to the first project targeting a vaccine to reduce E.coli bacteria in cattle. The second project will receive $9.6 million to develop mycobacterial cell…